(2R)-2-amino-2-cyclohexyl-N-[2-(1-methyl-1H-pyrazol-4-yl)-9-oxo-3,10,11-triazatricyclo[6.4.1.04,13]trideca-1,4(13),5,7,11-pentaen-6-yl]acetamide

• ChemBase编号: 155048
• 分子式: C22H25N7O2
• 平均质量: 419.4796
• 单一同位素质量: 419.20697308
• SMILES: Cn1cc(cn1)c1c2c3c(cc(cc3[nH]1)NC(=O)[C@@H](C1CCCCC1)N)c(=O)[nH]nc2
• Canonical SMILES: Cn1ncc(c1)c1[nH]c2c3c1cn[nH]c(=O)c3cc(c2)NC(=O)[C@@H](C1CCCCC1)N
• InChI: InChI=1S/C22H25N7O2/c1-29-11-13(9-25-29)20-16-10-24-28-21(30)15-7-14(8-17(27-20)18(15)16)26-22(31)19(23)12-5-3-2-4-6-12/h7-12,19,27H,2-6,23H2,1H3,(H,26,31)(H,28,30)/t19-/m1/s1
• InChIKey: NDEXUOWTGYUVGA-LJQANCHMSA-N

名称和登记号

名称

• IUPAC标准名: (2R)-2-amino-2-cyclohexyl-N-[2-(1-methyl-1H-pyrazol-4-yl)-9-oxo-3,10,11-triazatricyclo[6.4.1.0^4,^1^3]trideca-1,4(13),5,7,11-pentaen-6-yl]acetamide
• IUPAC传统名: (2R)-2-amino-2-cyclohexyl-N-[2-(1-methylpyrazol-4-yl)-9-oxo-3,10,11-triazatricyclo[6.4.1.0^4,^1^3]trideca-1,4(13),5,7,11-pentaen-6-yl]acetamide
• 别名: (2R)-2-Amino-2-cyclohexyl-N-[2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl]-acetamide; PF-00477736; PF-477736; (10R)-9,10,11,12-Tetrahydro-10-methyl-3-(6-methyl-3-pyridinyl)-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one; PF-3644022; (αR)-α-Amino-N-[5,6-dihydro-2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1H-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]cyclohexaneacetamide; PF 477736

登记号

• CAS号: 952021-60-2; 1276121-88-0
• MDL号: MFCD16038847
• PubChem SID: 162249186
• PubChem CID: 16750408

理论计算性质

• Acid pKa: 11.40662
• 质子受体: 5
• 质子供体: 4
• LogD (pH = 5.5): -0.90019315
• LogD (pH = 7.4): 0.7424277
• Log P: 1.7235576
• 摩尔折射率: 130.8941 cm^3
• 极化性: 46.442245 Å^3
• 极化表面积: 130.19 Å^2
• 可自由旋转的化学键: 4
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO: ≥20 mg/mL
• 外观: yellow powder

安全信息

• 德国WGK号: 3
• 保存温度: 2-8°C

产品相关信息

• 纯度: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C22H25N7O2

详细说明

Sigma Aldrich - PZ0186

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
PF-00477736 is a potent, selective ATP-competitive small-molecule inhibitor that inhibits Chk1 with a Ki of 0.49 nM. The compound abrogates cell cycle arrest induced by DNA damage and enhances cytotoxicity of clinically important chemotherapeutic agents, including gemcitabine and carboplatin.

Toronto Research Chemicals - P293825

PF-3644022 is a potent freely reversible ATP-competitive compound that inhibits MK2 activity (Ki = 3 nM) with good selectivity when profiled against 200 human kinases. PF-3644022 is a benzothiophene inhibitor of mitogen-activated protein kinase-activated

Toronto Research Chemicals - P293850

P293850 is a selective checkpoint kinase 1 (Chk1) inhibitor (Ki values are 0.49 and 47 nM for Chk1 and Chk2 respectively). Abrogates cell cycle arrest at S and G2-M checkpoints; sensitizes cells to DNA damage.

参考文献

• Hegen, M., et al.: J. Immunol., 177, 1913 (2006)
• Anderson, D., et al.: J. Med. Chem., 50, 2647 (2006)
• Goldberg, D., et al.: Bioorg. Med. Chem. Lett., 18, 938 (2006)
• Burnette, B., et al.: Pharmacology, 84, 42 (2006)
• Mourey, et al.: J. Pharmacol. Exp. T
• Ashwell, et al.: Clin. Cancer Res., 14, 4032 (2008)
• Blasina, et al.: Mol. Cancer Ther., 7 2394 (2008)
• Zhang, et al.: Clin. Cancer Res., 15 4630 (2008)